- Home
- PRA vs ZLAB Comparison
PRA vs ZLAB Comparison
Compare PRA & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PRA | ZLAB |
|---|---|---|
| Founded | 1976 | 2013 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 2.0B |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | PRA | ZLAB |
|---|---|---|
| Price | $24.20 | $17.22 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 6 |
| Target Price | $22.50 | ★ $57.22 |
| AVG Volume (30 Days) | 368.6K | ★ 918.9K |
| Earning Date | 11-04-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.66 | N/A |
| Revenue | ★ $1,120,385,000.00 | $441,629,000.00 |
| Revenue This Year | N/A | $30.20 |
| Revenue Next Year | $1.24 | $34.71 |
| P/E Ratio | $36.85 | ★ N/A |
| Revenue Growth | N/A | ★ 24.14 |
| 52 Week Low | $13.90 | $16.82 |
| 52 Week High | $24.41 | $44.34 |
Technical Indicators
Market Signals| Indicator | PRA | ZLAB |
|---|---|---|
| Relative Strength Index (RSI) | 59.46 | 19.27 |
| Support Level | $24.14 | $16.82 |
| Resistance Level | $24.41 | $18.67 |
| Average True Range (ATR) | 0.10 | 0.58 |
| MACD | 0.03 | 0.06 |
| Stochastic Oscillator | 61.61 | 11.53 |
Price Performance
Historical ComparisonAbout PRA ProAssurance Corporation
ProAssurance Corp is a holding company for property and casualty insurance companies. The company's wholly-owned insurance subsidiaries provide professional liability insurance for healthcare professionals and facilities, professional liability insurance for attorneys, and workers' compensation insurance. ProAssurance reports operating results in five segments: Specialty Property and Casualty, Workers' Compensation, Segregated Portfolio Cell Reinsurance, Lloyd's Syndicate, and Corporate. ProAssurance generates the vast majority of its revenue from its Specialty P&C activities, followed by Worker's Compensation.
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.